September 22, 2014: In the persistent struggle to raise their companies’ stock prices, CEOs relentlessly search for the most effective strategies to bring value to a company while keeping the bottom line lean and mean.
September 18, 2014: Bayer announced today will spin off its plastics unit as the company moves further toward focusin solely on the life sciences market. The plastics unit is valued at around $10 billion and Bayer’s supervisory board has unanimously approved the plans.
September 18, 2014: The FDA has contacted Flexion Therapeutics to let them know a clinical hold had been put on patient enrollment and dosing for an ongoing Phase 2b clinical trial.
September 18, 2014: Boehringer Ingelheim and CureVac have entered an exclusive global license and development partnership to focus on CureVac’s CV9202, netting CureVac $556 million ($45 million upfront).